Safety and Efficacy of Pasireotide LAR (PAS) in Patients with Advanced Neuroendocrine Tumors (NET): Findings of a Phase I, Multi-center, Open-label, Dose-escalation Study

#1498

Introduction: PAS, a next generation SSA, is investigated to determine the maximum tolerated dose (MTD) in pts with advanced NET.

Aim(s): This phase I dose escalation and expansion (DE/DX) study evaluated the MTD of PAS in patients with advanced NET. Results of a planned interim analysis are presented.

Materials and methods: Pts were enrolled in 2 phases: DE phase (to determine the MTD after minimum of 2 treatment cycles) at starting a dose of 80 mg PAS i.m. followed by a dose expansion phase.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Yao J, Chan J, Mita A, Kundu M, Valera S,

Keywords: Pasireotide, MTD,